FDA Approves First Oral Microbiota Biotherapeutic for Recurrent C. difficile Infection
Vowst is the first and only FDA-approved orally administered microbiota-based therapeutic for the prevention of recurrent C. diff infection in adults.
Friday's 5 Quotes for Primary Care 4-28-2023
"Disconnect" on anticoagulation between MDs and patients; NASH resolves after bariatric surgery; antiobesity medications are not weight-loss drugs; plus 2 more updates of note.
Tirzepatide Delivers Weight Loss of 15.7% in Adults with Overweight, Obesity
Dubbed the "twincretin," the GLP-1/GIP RA met weight and HgbA1c reduction endpoints, with nearly half of tirzepatide-treated patients achieving weight loss of at least 15%.
Professional Societies, Concerned Clinicians Create Guides to Navigate Burnout
The AHRQ, Mayo Clinic, AMA, and National Academy of Medicine each recommend actions steps for all organizational levels to help build more supportive environments.
Antiobesity Medications Compliment Lifestyle Change in an Optimal Weight Management Plan: Obesity Expert
For persons diagnosed with obesity, a prescription antiobesity medication is just one part of optimal care that includes significant lifestyle change as well, says Caroline Apovian, MD.
Melatonin Gummies May Have a Higher Dose than Indicated on Label, Putting Children at Risk
In gummy products with melatonin, the actual amount ranged from 74% to 347% of the labeled quantity, according to a new analysis.
Daily Dose: Physician and Patient Perspectives on Oral Anticoagulation for AF
Your daily dose of clinical news you may have missed.
The First Antiobesity Medications to Simulate Human Physiology are Indicated for Long-term Treatment
Apovian: GLP-1 receptor agonists are the first antiobesity medications to simulate human physiology, which is why they sustain weight loss and are meant for long-term use.
Obesity & Pain Management: A Primary Viewpoints Podcast
In our latest episode, an obesity medicine physician explains the importance of a comprehensive plan to manage chronic pain in patients with obesity.
"Disconnect" on Oral Anticoagulation Observed Between Patients with AF and their Physicians
More than two-thirds of patients not receiving OAC were open to beginning treatment but many of their physicians were not, according to a study of PINNACLE Registry participants.
Daily Dose: RSV Infection in Infancy & Risk of Asthma in Childhood
Depression Linked to Hormonal Contraception Associated with Higher Risk of Postpartum Depression in Large Study of First-time Mothers
Women with prior HC-associated depression had a higher risk of developing a depressive episode during pregnancy and postpartum than women with non-HC-associated depression.
Metabolic Syndrome and Poor Fitness in Women Increase Long-term CVD Risk: New Research
Women with ischemic heart disease who were metabolically unhealthy but fit were more than 50% more likely to experience a major adverse cardiovascular event.
RSV Infection During Infancy Linked to Higher Risk of Asthma in Childhood
Results from a prospective birth cohort study show an age-dependent association between RSV infection during infancy and childhood asthma.
Daily Dose: Weight Loss Surgery & Bone Health in Adolescents
FDA Clears Omnipod GO Insulin Delivery Device for Persons with Type 2 Diabetes
The wearable tubeless insulin delivery device provides a fixed rate of continuous long-acting insulin for 72 hours, requiring no needles or injections.
Bariatric Surgery Associated with NASH Resolution in Randomized, Open-label Trial
In persons with biopsy-confirmed NASH, the probability of disease resolution was more than 3X greater after RGB or SG vs lifestyle intervention at 52 weeks.
The GLP-1 Receptor Agonist Agents are Antiobesity Medications, Not Weight-loss Drugs
Caroline Apovian, MD, highlights how drugs like semaglutide 2.4 mg treat the chronic relapsing disease of obesity and why a distinction from "weight-loss drugs" is critical.
Fluvoxamine and Inhaled Budesonide: Novel Combination Reduced Incidence of Severe COVID-19
When combined, fluvoxamine and inhaled budesonide appear more likely than either agent alone to reduce risk of early COVID-19 becoming severe, say TOGETHER investigators.
Daily Dose: Vaping Among Early Adolescent Cigarette Smokers